1. OlsenWC, Doshan H, Zhan Cet al.: Prolonged coating of CCR5 lymphocytes by PRO 140, a humanized CCR5 monoclonal antibody for HIV-1 therapy. Presented at:13th Conference on Retroviruses and Opportunistic Infections.Denver, CO, USA, 5–8 February 2006, Abstract 515.
2. OlsenWC, Nagashima K, Rosenfield S, Maddon P: Potent synergistic inhibition of HIV-1 by combinations of the viral entry inhibitors PRO542 and T-20. Presented at:40th (ICAAC) Interscience Conference on Antimicrobial Agents and Chemotherapy.Toronto, ON, Canada, 17–20 September 2000, Abstract 549.
3. Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542
4. NorrisD, Morales J, Godofsky Eet al.: TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in Phase 2 study at 48 weeks. Presented at:XVI International AIDS Conference.Toronto, Canada, 13–18 August 2006, Abstract THLB0218.
5. MoyleGE, DeJesus M, Boffito Ret al.: CXCR4 antagonism: proof of activity with AMD11070. Presented at:14th Conference on Retroviruses and Opportunistic Infections.Los Angeles, CA, USA, 25–28 February 2007, Abstract 511.